MARC-2: An open-label trial to characterize patients with metastatic renal cell carcinoma (mRCC) treated with everolimus after failure of the first VEGFR-TKI therapy.

被引：0
|
作者：
Staehler, Michael D.
Bergmann, Lothar
Gruenwald, Viktor
Huschke, Torsten
Keilholz, Ulrich
Ohlmann, Carsten Henning
Stoeckle, Michael
Weigang-Koehler, Karin
Hauswald, Kirsten
Schaller, Felix
Strassl, Luise
Junker, Kerstin
机构：
[1] Univ Hosp Grosshadern, Munich, Germany
[2] Dept Med, Frankfurt, Germany
[3] Univ Canc Ctr Frankfurt, Frankfurt, Germany
[4] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany
[5] Univ Hosp Jena, Jena, Germany
[6] Charite, Dept Hematol & Med Oncol, CBF, Berlin, Germany
[7] Univ Saarland, Homburg, Germany
[8] Hosp Nurnberg, Nurnberg, Germany
[9] IOMEDICO AG, Freiburg, Germany
[10] Univ Hosp Jena, Dept Urol, Jena, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 05期
关键词：
D O I：
10.1200/jco.2012.30.5_suppl.467
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
467
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy.
    Xie, Wanling
    DiNatale, Renzo
    Hakimi, A. Ari
    Donskov, Frede
    Porta, Camillo
    Reaume, M. Neil
    Basappa, Naveen S.
    Hansen, Aaron Richard
    Rini, Brian I.
    Beuselinck, Benoit
    Bjarnason, Georg A.
    Srinivas, Sandy
    Brugarolas, James
    Rha, Sun Young
    Wood, Lori
    Lalani, Aly-Khan A.
    Bosse, Dominick
    Duquette, Audrey
    Heng, Daniel Yick Chin
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [32] Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
    Armstrong, Andrew J.
    Halabi, Susan
    Eisen, Tim
    Broderick, Samuel
    Stadler, Walter M.
    Jones, Robert J.
    Garcia, Jorge A.
    Vaishampayan, Ulka N.
    Picus, Joel
    Hawkins, Robert E.
    Hainsworth, John D.
    Kollmannsberger, Christian K.
    Logan, Theodore F.
    Puzanov, Igor
    Pickering, Lisa M.
    Ryan, Christopher W.
    Protheroe, Andrew
    Lusk, Christine M.
    Oberg, Sadie
    George, Daniel J.
    LANCET ONCOLOGY, 2016, 17 (03): : 378 - 388
  • [33] Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study
    Bergmann, Lothar
    Goebell, Peter J.
    Kube, Ulrich
    Kindler, Manfred
    Herrmann, Edwin
    Janssen, Jan
    Schmitz, Joerg
    Weikert, Steffen
    Steiner, Gabriel
    Jakob, Andreas
    Staehler, Michael D.
    Steiner, Thomas
    Overkamp, Friedrich
    Albrecht, Michael
    Guderian, Gernot
    Doehn, Christian
    ONKOLOGIE, 2013, 36 (03): : 95 - 100
  • [34] Phase III, randomized, placebo-controlled study of everolimus in patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients intolerant of prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy
    Hutson, T. E.
    Bracarda, S.
    Escudier, B.
    Porta, C.
    Figlin, R. A.
    Calvo, E.
    Grunwald, V.
    Ravaud, A.
    Kpamegan, E.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [35] Thrombospondin-2 and LDH: potential predictive biomarkers for the treatment of metastatic renal cell carcinoma with everolimus after one VEGF-targeted therapy (MARC-2 study)
    Zeuschner, Philip
    Hoelters, Sebastian
    Stoeckle, Michael
    Seliger, Barbara
    Mueller, Anja
    Bachmann, Hagen S.
    Gruenwald, Viktor
    Christoph, Daniel C.
    Stenzl, Arnulf
    Grimm, Marc-Oliver
    Bruening, Fabian
    Goebell, Peter J.
    Augustin, Marinela
    Roos, Frederik
    Harde, Johanna
    Benz-Rued, Iris
    Staehler, Michael
    Junker, Kerstin
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 99 - 99
  • [36] RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3 STUDY OF EVEROLIMUS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): SUBGROUP ANALYSIS OF PATIENTS INTOLERANT OF PRIOR VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR (VEGFR-TKI) THERAPY
    Bracarda, S.
    Escudier, B.
    Porta, C.
    Hutson, T. E.
    Figlin, R. A.
    Calvo, E.
    Grunwald, V.
    Ravaud, A.
    Kpamegan, E.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2010, 21 : 292 - 292
  • [37] Erectile function in patients with metastatic renal cell carcinoma treated with first-line therapy.
    Tsimafeyeu, Ilya
    Zukov, Ruslan
    Borisov, Pavel S.
    Leonenko, Valentina
    Kuznetsov, Vladimir
    Bondarenko, Anastasia
    Tishova, Yulia
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 383 - 383
  • [38] Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial (vol 16, pg 1479, 2015)
    Motzer, R. J.
    Hutson, T. E.
    Glen, H.
    LANCET ONCOLOGY, 2016, 17 (07): : E270 - E270
  • [39] Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial (vol 16, pg 1473, 2015)
    Motzer, R. J.
    Hutson, T. E.
    Glen, H.
    LANCET ONCOLOGY, 2018, 19 (10): : E509 - E509
  • [40] Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
    Hutson, Thomas E.
    Lesovoy, Vladimir
    Al-Shukri, Salman
    Stus, Viktor P.
    Lipatov, Oleg N.
    Bair, Angel H.
    Rosbrook, Brad
    Chen, Connie
    Kim, Sinil
    Vogelzang, Nicholas J.
    LANCET ONCOLOGY, 2013, 14 (13): : 1287 - 1294
12345